8.26.2007

Biotechnology Management, Kellogg School of Management

Biotechnology Management, Kellogg School of Management: "

BIO-TechVenture
Winter Quarter 2006

Leadership positions open for 2006
This year, students will be traveling to either San Francisco, Boston/New Jersey or San Diego to visit industry leaders and learn more about the biotechnology sector.

Congratulations to the winner of the BioTech Ventures Best Paper Award
The Evolving Role of Marketing in Biotechnology Dario Benavides, Lanier Coles, Gary Dulaney, Vanessa Rath and Carla Yager.

The Biotech Ventures course benefits students
The speakers gave me a great landscape of current successes and challenges they face and the company visits really brought it to life."
-
Peggy Mathias '03

And hosting firms
"Fortunately, I have experienced the program from two perspectives, both as a student and an employee of a hosting firm. The program is a great way for companies to build and foster a valuable relationship with a top business school. Furthermore, the course cultivates honest dialogue between companies and academia about the application of business principles to the day-to-day challenges and opportunities faced by the medical industry." -Katie Arnold '01, Medical Device firm

"We believe the student visit was very beneficial for us to learn about the current best thinking of the biotech business."
-
Gangfeng Xu '02, Pharmaceutical firm

Students at IDEC
Bio-TechVentures goes to Biotech Bay (March 2003)
William H. Rastetter, Ph.D., Chairman and Chief Executive Officer for IDEC is surrounded by Kellogg Biotech Tech Venture students at IDEC Pharmaceuticals Corporation, San Diego

Winter 2006
The Kellogg School's Bio-TechVenture 918C, is a survey course that provides students with a framework to understand the trends and patterns shaping the biotechnology sector. This course blends a theoretical study of concepts with hands-on projects, including a mix of lectures, guest speakers, and a weeklong research expedition to a biotechnology cluster.

The key to understanding the biotech/pharmaceutical sector is to be able to predict patterns. These patterns will emerge through continuous exposure to the many examples. Tech Ventures gives you a unique opportunity to study the workings of 25-30 biotech, pharmaceutical and venture firms. By gathering primary data and interviews from the organizations, you will be able to understand the interaction of industry trends, key players, and strategies. Students will learn to recognize technologies and their impact on venture and industry developments.

This course is student-driven. Students will have an opportunity to:
  • obtain leadership positions in biotech through one of the many committees;
  • design the course to individual interests through participation
    in TechVenture committees;
  • work on self-selected class projects;
  • explore recruiting opportunities.
Course Objectives
  • Give students an understanding of the importance of the biotechnology sector in the US and global economy.
  • Provide an understanding of the management issues and challenges of developing a biotechnology company.
  • Provide students with a first hand experience of emerging companies and technologies as they develop in real-time.
  • Develop the student's instinct to identify trends in the sector.
  • Provide students with the experience and skills of researching and writing a publishable paper or case study, alternatively (sample 2002 papers).
  • Enhance the presence of the Kellogg School within the biotechnology community through interactions with the key thought leaders in the industry.
Companies we visited
East Coast
San Francisco Area
Alkermes, Inc.
ARIAD Pharmaceuticals, Inc.
AVANT Immunotherapies, Inc.
Boston Scientific
Biogen
Genzyme Corporation
ImmunoGen, Inc.
Millennium Pharmaceuticals
MPM Capital
ViaCell
Whitehead Institute
Wyeth
Merck
J&J

CV Therapeutic
Roche Molecular Systems, Inc.
Guidant Corporation
Nuvelo, Inc.
Becton Dickinson
Affymetrix, Inc.
Applied Biosystems
Avigen
Scios Inc.
Versant Ventures
Genentech, Inc.
Tularik, Inc.
Vaxgen
InterWest Partners
Abgenix

"